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Background: Hereditary diffuse gastric carcinoma is an autosomal dominant cancer syndrome associated with
mutations of the E-cadherin gene (CDH1). E-cadherin is normally involved in cell-cell adhesion, so it not surprising
that individuals with this syndrome are predisposed to develop malignancies with dyshesive morphologies at a
young age, such as diffuse (signet ring cell) gastric carcinoma and lobular breast carcinoma. Herein we describe the
first reported case of primary appendiceal signet ring cell carcinoma arising in a CDH1-associated hereditary diffuse
gastric carcinoma kindred with synchronous primary diffuse gastric carcinoma.
Case presentation: A 51- year old woman, with known CDH1 mutation carrier status and a prior history of lobular
breast carcinoma underwent prophylactic total gastrectomy which revealed multifocal intramucosal signet ring cell
carcinoma. An appendectomy was performed at the same time due to a prior episode of presumed appendicitis,
with pathologic examination significant for a primary signet ring cell carcinoma of the appendix.
Conclusion: As appendiceal signet ring cell carcinoma is exceedingly rare, the occurrence of this neoplasm in this
patient, with this particular morphology, provides credence for it being part of the hereditary diffuse gastric
carcinoma spectrum of malignancies.
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Hereditary diffuse gastric carcinoma is an autosomal dom-
inant cancer syndrome accounting for approximately 1 to
3% of all gastric carcinoma, associated with mutations of
the E-cadherin (Cadherin-1; CDH1) gene [1-3]. It is char-
acterized by high penetrance with an approximate 80% life-
time risk of developing diffuse gastric carcinoma [2]. Early
onset diffuse gastric carcinoma is pathognomonic for
HDGC and the natural history is the insidious develop-
ment of intramucosal signet ring cell carcinoma in early
adulthood progressing to advanced gastric carcinoma by* Correspondence: leslie.e.hamilton@gmail.com
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reproduction in any medium, provided the ormid-adulthood, at a mean age of 40 years [1]. Female
kindreds also have a predisposition for lobular carcinoma
of the breast. Established clinical diagnostic criteria for
HDGC, as defined by the International Gastric Cancer
Linkage Consortium, include: (1) two or more first or
second degree relatives with confirmed diffuse (signet
ring cell) gastric carcinoma, with at least one diagnosed
before 50 years of age; or (2) three or more confirmed
cases of diffuse gastric carcinoma amongst first and sec-
ond degree relatives, independent of age of onset [4].
Additional clinical indications for genetic testing for
CDH1 mutations include: HDGC in two relatives with
histologic confirmation of tumor in only one individual,
diffuse gastric carcinoma in an individual < 40 years re-
gardless of family history, or individuals and families withal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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before 50 years of age) and lobular breast carcinoma [2].
Multifocal intramucosal carcinoma of stomach is ap-
parent by the age of 20-to-30 years, preferentially at the
body-antrum interface [1]. The cumulative risk of ad-
vanced carcinoma is 1% at age 20, 4% at age 30, 21%
(male) to 46% (female) at age 50 and 67% (male) to 83%
(female) at age 80 [1,2,5]. Therefore management in-
cludes surveillance endoscopy (every 6 to 12 months) as
early as age 16 and consideration of prophylactic gas-
trectomy in early adulthood. Unfortunately, the insidious
and multifocal nature of early signet ring cell carcinoma
diminishes the sensitivity of endoscopic detection with
current techniques, and prophylactic gastrectomy should
be considered for any individual with a CDH1 muta-
tion, regardless of the results of endoscopic surveillance
[1,2,6]. This is further supported by pathologic reviews of
prophylactic gastrectomies in CDH1 individuals. In the
largest study to date, 96% of gastrectomy specimens
contained early diffuse gastric carcinoma, of which only
9% had similar lesions identified on pre-operative endo-
scopic biopsies. When this data was included with all
previous published data on prophylactic total gastrec-
tomies (a total of 93 cases) 92.5% of specimens contained
signet ring cell lesions [7,8].
Female carriers of the CDH1 mutation also have a pre-
disposition for lobular breast carcinoma. It is likely that
there are interfamilial differences, but the cumulative
lifetime risk of breast cancer is reportedly as high as
39 to 52% in HDGC kindreds [5,9,10]. Female carriers
should be referred to a high-risk breast cancer screening
clinic prior to the age of 40 years. Nevertheless, the pene-
trance for gastric carcinoma is much higher and female
carriers are five times more likely to develop gastric car-
cinoma than lobular breast carcinoma [5]. Interestingly,
female carriers have a much higher cumulative risk for
gastric adenocarcinoma than male carriers in the same
age cohorts [1,2,5]. Furthermore, pathologic analysis
of prophylactic gastrectomies in a case series of CDH1-
associated HDGC families documented a trend towards
more severe disease burden in females within one cohort,
with larger invasive foci and an increased total number of
foci [11]. The reasoning for this is not clear; hormonal or
other environmental factors presumably participate in
the pathogenesis of HDGC tumors.
With respect to the molecular pathogenesis of HDGC,
it is not surprising that the CDH1 mutation predisposes
to malignancies with a dyshesive signet ring cell morph-
ology such as diffuse gastric carcinoma and lobular breast
carcinoma. Approximately 25-50% of families with HDGC
syndrome have an inactivating germline mutation of the
tumor suppressor gene Cadherin-1 (CDH1) that encodes
E-cadherin [1,2,12]. E-cadherin has an important role in
cell adhesion, motility, proliferation and differentiation. Itsprimary role is that of an epithelial transmembrane
glycoprotein that functions as a cell-cell adhesion mol-
ecule; normal E-cadherin also interacts with β-catenin to
form complexes with actin, mediating the linkage of cells
to the cytoskeleton. When CDH1 is mutated, there is loss
of normal cell adhesion and cell polarity; disaggregation
of cells also promotes local invasion and metastases of
neoplastic cells, and loss of CDH1 is a common molecu-
lar event in advanced sporadic malignancies [13-16]. The
majority of inactivating germline mutations in HDGC
families are of the truncating type (75% of cases); the
remaining 25% are of the missense type [1]. Somatic
inactivation of the second allele is thought to result
from promoter hypermethylation, mutations of CDH1,
or loss of heterozygosity [2,5,17]. Although typically
there is an absence or reduced staining of neoplastic
cells by E-cadherin, some studies have documented limited
E-cadherin staining by immunohistochemistry in HDGC-
associated carcinomas [5]. Interestingly, one genetic study
of HDGC kindreds found one family with an intact sec-
ond CDH-1 allele and detectable E-cadherin protein in
neoplastic cells, and postulated that a 50% reduction in
CDH-1 function may be enough to promote tumorigen-
esis; other explanations include: a dominant-negative ef-
fect of the germline mutation or a missense mutation of
the wild-type allele [13]. Furthermore, 50% of sporadic
cases of diffuse gastric carcinoma and lobular breast car-
cinoma are also associated with inactivation of CDH1 and
loss of E-cadherin expression, most frequently through
promoter methylation [17]; this event appears to be critical
for the development of tumors with this unique morpho-
logic phenotype.
Anecdotal occurrences of primary malignancies of the
colon, lung, prostate, salivary gland and pancreas have
been described in CDH-1 associated HDGC families,
with rare examples of the signet ring cell variety; none
of which occur at a frequency greater than the general
population [18]. Colorectal carcinoma has been deemed
by some to be an occasional member of the HDGC dis-
ease spectrum, with the recommendation that surveil-
lance colonoscopy should commence in this population
at age 40, or 10 years younger than the youngest diagno-
sis of colon carcinoma [1,2,19,20]. In the general popula-
tion, colorectal carcinoma is thought to be familial in
20% of cases. Several studies have documented mutations
of CDH1 in cell lines and tissue samples from colorectal
carcinoma, albeit rarely [14,15,21-24]. Only three of these
studies correlated the expression of E-cadherin with
the morphology of the carcinoma from which the cell
line/tissue sample was derived; as expected, loss of ex-
pression of E-cadherin typically correlated with a poorly
differentiated/signet ring cell growth pattern [15,21,23].
Alteration of the association between E-cadherin and
β-catenin may represent an alternative tumorigenesis
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cohort [21].
In the English literature, there are at least twenty-six
reported cases of colorectal carcinoma occurring in
CDH1-associated HDGC kindreds; an additional eight
cases of colorectal carcinoma exist in families with a his-
tory of diffuse gastric carcinoma that have tested nega-
tive for CDH1 mutations and did not meet the criteria
for hereditary nonpolyposis colon cancer (HNPCC)
[8-10,12,13,15,18,24-30]. It is likely that a proportion of
these cases represent sporadic colorectal carcinomas un-
related to HDGC. Albeit rare (the reported incidence is
less than 1% in most case series [31-36]), signet ring cell
carcinoma of the colorectum would be expected to
occur more frequently in individuals with HDGC than
the general population given its morphology. However
there is a paucity of data on the histology of colorectal
carcinomas occurring in the HDGC population, as most
studies simply comment on the organ of involvement of
extra-gastric malignancies. Of reported cases, only one
has been diagnosed as a signet ring cell carcinoma; there
is at least one additional case of a colonic signet ring cell
carcinoma occurring in a family with familial gastric car-
cinoma that tested negative for the CDH1 mutation (and
negative for HNPCC) [12,28].
Notably there is an absence of any reported cases of
primary appendiceal carcinomas in HDGC kindreds in
the English literature. Herein we describe a case of pri-
mary appendiceal signet ring cell carcinoma arising in a
51 year old female from a CDH1-associated HDGC kin-
dred who underwent an interval appendectomy at the time
of a prophylactic gastrectomy. This is the first reported
case of synchronous gastric and appendiceal signet ring cell
carcinomas in HDGC. As appendiceal signet ring cell car-
cinoma is exceedingly rare, the occurrence of this neo-
plasm in this patient provides credence for it being part of
the HDGC spectrum of malignancies.
Case presentation
A 51 year old female from a known HDGC kindred was
status/post mastectomy and adjuvant chemoradiation
for invasive mammary carcinoma six years prior. Her
family history was significant for a sister with metastatic
gastric adenocarcinoma (deceased at age 41), two aunts
and one cousin with gastric carcinoma (diagnosed in
40s, two of which are deceased), and a brother and niece
identified as CDH1 mutation carriers. Genetic screening,
performed one year after her mastectomy, confirmed
that she was also a CDH1 gene mutation carrier. She
elected to undergo a prophylactic total gastrectomy;
prior to this her only gastrointestinal symptom was non-
specific mild constant epigastric discomfort, and two sur-
veillance endoscopic biopsies of the stomach, one year
apart, were negative for carcinoma. One month prior tosurgery, she was treated medically with antibiotics at
an outside community hospital for presumed acute ap-
pendicitis, a diagnosis supported by CT-imaging find-
ings. Given this history, an interval appendectomy was
completed at the time of the total gastrectomy with
Roux-en-Y esophagojejunostomy. At laparotomy, the
17 x 11 centimetre-stomach lacked lymphadenopathy,
and its serosa, wall and mucosa were all intact and unre-
markable. The appendix was enlarged and indurated with
serosal adhesions.
At gross examination, the stomach was unremarkable;
representative sections were submitted for histologic exam-
ination, including ten sections each from the proximal
body, mid-body, angularis (body/antrum interface), and an-
trum, and five sections each from the proximal and distal
margins; each section was sampled to ensure circumferen-
tial representation. Ten lymph nodes were identified within
the regional adipose tissue. The appendix was intact with
adherent hemorrhagic adhesions of its serosa, and with
clear gelatinous luminal contents; the appendix was sub-
mitted in toto for histologic examination.
Histology delineated 25 foci of signet ring cell carcinoma
confined to the lamina propria (intramucosal) of the prox-
imal gastric fundus. These foci were composed of single
cells and loose clusters of cells with mucin vacuoles that
dispersed the nucleus to the periphery (Figure 1A); the lar-
gest focus was 0.2 cm in diameter. No mural invasion or
regional nodal metastases were identified, resulting in a
final pathologic stage of pT1N0.
The appendiceal wall was replaced by an infiltrative neo-
plasm composed of clusters and columns of cells with
mucin vacuoles that dispersed the nucleus to the periphery.
Signet ring cells composed more than 50% of the tumor
volume, with focal mucin lakes (Figure 2A). The malig-
nancy invaded the lymphatics and the mesoappendiceal
adipose tissue. A precursor adenoma with low grade dys-
plasia replaced the appendiceal mucosa, providing cre-
dence for a primary carcinoma. Both the appendiceal
signet ring cell carcinoma and adenoma extended to the
proximal margin of the appendectomy specimen.
Despite the synchronous gastric and appendiceal carcin-
omas focally sharing similar histomorphology, they had
divergent immunohistochemical phenotypes. The gastric
carcinomata were cytokeratin 7 (Figure 1B), cytokeratin 20
(Figure 1C), and weakly E-cadherin positive (Figure 1D),
and negative for CDX-2 (Figure 1E), estrogen receptor and
mammoglobin. The appendiceal carcinoma was cyto-
keratin 20 (Figure 2B), CDX-2 (Figure 2C) and E-cadherin
positive but negative for cytokeratin 7 (Figure 2D), and es-
trogen receptor (Figure 2E). In addition, the appendiceal
carcinoma was negative for synaptophysin, excluding a
neuroendocrine neoplasm.
Given the diagnosis of an appendiceal malignancy, colon-
oscopy was performed post-operatively and was negative
Figure 1 Intramucosal Gastric Signet Ring Cell Carcinoma (x 20 magnification). (A) Hematoxylin- and eosin-stained section of gastric
mucosa with a focus of infiltrating cells having prominent mucin vacuoles and peripheral displacement of nuclei. By immunohistochemistry, the
signet ring cells show strong positivity for Cytokeratin 7 (B) and Cytokeratin 20 (C), weak positivity for E-cadherin (D), and negativity for CDX2 (E).
Hamilton et al. BMC Gastroenterology 2013, 13:114 Page 4 of 6
http://www.biomedcentral.com/1471-230X/13/114for distal lesions. One week subsequent to the laparot-
omy, a right hemicolectomy was performed to complete
resection and stage the appendiceal tumor. Signet ring
cell carcinoma was identified at the appendiceal orifice
and had disseminated to three pericolic lymph nodes,
with a final pathologic stage of pT3N1. Post-operative re-
covery was unremarkable; further management included
adjuvant chemotherapy.
Pathologic review of the previous mammary carcinoma
confirmed an invasive carcinoma of the breast, of lobular
phenotype with classic signet ring cell morphology, and as-
sociated lobular carcinoma in situ.Figure 2 Appendiceal Signet Ring Cell Carcinoma (x 20 magnifica
wall with extensive infiltration by columns and groups of cells having
By immunohistochemistry, the signet ring cells show strong positivity
Cytokeratin 7 (D) and estrogen receptor (E).Conclusions
In summary, we present the first case report of an
appendiceal signet ring cell carcinoma in an individual
with synchronous CDH1-associated hereditary diffuse
gastric carcinoma. The occurrence of this unusual tumor,
alongside other malignancies with a dyshesive signet ring
cell morphology, gives further credence to its inclusion in
the spectrum of HDGC disease. With an estimated inci-
dence of 0.12 cases per one million people per year and
representing 0.3 to 1.4% of all appendectomy specimens
[37-40], primary malignancies of the appendix are a rare
occurrence in the general population, and as in this case,tion). (A) Hematoxylin- and eosin-stained section of appendiceal
prominent mucin vacuoles and peripheral displacement of nuclei.
for Cytokeratin 20 (B) and CDX2 (C) and negativity for
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of cases in the SEER database are mucinous adenocarcin-
omas, with signet ring cell carcinomas comprising only
4% [37,38]. The diagnosis of signet ring cell carcinoma is
rendered when a tumor contains at least 50% of cells with
signet ring cell morphology, often associated with focal
mucinous differentiation. A signet ring cell histology in
appendiceal tumors is significant as it portends a worse
prognosis, with larger tumor sizes at presentation, more
advanced stage/distant disease at presentation and worse
survival outcomes, as compared to other types of primary
appendiceal malignancies [37-39,41].
Prior to making a diagnosis of signet ring cell carcin-
oma, it is important to exclude a metastasis from a sig-
net ring cell carcinoma at another site; this is critical in
the setting of a hereditary cancer syndrome that predis-
poses to malignancies of similar morphology at differ-
ent sites. There are reported cases of gastric signet ring
cell carcinoma, metastasizing to the appendix, mimick-
ing a primary appendiceal malignancy [42]. Another
consideration is that second primary synchronous and
metachronous neoplasms occur in up to 35% of patients
with an appendiceal carcinoma, typically in the colorectum
[43,44]. In our case, although the appendiceal and gastric
malignancies focally share similar histologic features, their
immunohistochemical patterns are distinct and con-
sistent with a primary malignancy at each site. Fur-
thermore, their immunohistochemical patterns are distinct
from the expected staining pattern of a metastatic lobular
breast carcinoma, an important consideration given the oc-
currence of this lesion in the spectrum of HDGC syn-
drome, and in this patient. In addition, adenomas are a
recognized precursor to signet ring cell carcinoma within
the colorectum [31] and the association of a villous aden-
oma with the appendiceal signet ring cell carcinoma, fur-
ther supports the primary nature of this malignancy.
Lastly, no synchronous primary or secondary colorectal
neoplasm was identified elsewhere in our patient.
Our patient’s prognosis is adversely affected by the
finding of a synchronous signet ring cell carcinoma of
the appendix. The ‘prophylactic’ total gastrectomy is
established as a curative procedure in HDGC, given the
high prevalence rate of early diffuse gastric carcinoma in
this cohort. However, this procedure is not without mor-
bidity and should be carefully considered in the manage-
ment of HDGC, especially since the risk of extra-gastric
malignancies is largely unknown. Furthermore, if symp-
toms attributable to the lower gastrointestinal system
exist in these individuals at risk for malignancy at mul-
tiple organ sites, consideration should be given for col-
onoscopy prior to prophylactic gastrectomy to provide
more definitive surgical management. It is likely that as
more individuals with HDGC syndrome are identified
early though genetic screening, and undergo prophylacticgastrectomy, longer survival outcomes will effectively
unveil additional risks of malignancy at other organ sites.
Further studies are needed to accurately define these extra-
gastric malignancies, not only to identify those individuals
and families with certain tumor types other than diffuse
gastric carcinoma that should be considered for genetic
testing, but to also better define the clinical guidelines for
the screening of malignancies in individuals with genetic-
ally proven HDGC.
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